Exhibit 99.7
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION
(as restated)
Introduction
The unaudited pro forma condensed combined balance sheet as of June 30, 2020 and the unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2020 and for the year ended December 31, 2019, combine the unaudited pro forma condensed combined financial statements of 180 with the financial statements of “KBL” c/k/a 180 Life Sciences Corp, f/k/a KBL Merger Corp IV. to give effect to the business combination. Additionally, the financial statements of 180 (where 180 refers to the post-combination results of 180 Life Sciences Corp. f/k/a CannBioRx Life Sciences Corp.), CBR Pharma, 180 LP and CannBioRx (where CannBioRx refers to the pre-combination results of 180 Life Sciences Corp. f/k/a CannBioRx Life Sciences Corp.) were combined to give effect to the Reorganization. The Reorganization and business combination are reflected as if they had occurred on January 1, 2019 with respect to the unaudited pro forma condensed combined statements of operations and on June 30, 2020 with respect to the unaudited pro forma condensed combined balance sheet.
Accounting for the Merger
The financial statements of KBL, 180, CBR Pharma, 180 LP, CannBioRx and Katexco were prepared in accordance with GAAP. In the Reorganization between 180 (the legal acquiree) and the 180 Subsidiaries (Katexco, CBR Pharma and 180 LP) which was consummated on July 16, 2019, it was determined that Katexco was the accounting acquirer and the remaining companies were the accounting acquirees. In the business combination between KBL and the newly combined 180, the business combination was accounted for as a reverse recapitalization of 180.
The unaudited pro forma condensed combined financial information should be read in conjunction with the financial statements of each of KBL, 180 and the 180 Subsidiaries.
The unaudited pro forma condensed combined financial information includes reclassifications to conform the 180 Subsidiaries’ historical accounting presentation to 180’s accounting presentation.
The unaudited pro forma adjustments give effect to events that are directly attributable to the transactions and are based on available data and certain assumptions that management believes are factually supportable. In addition, with respect to the unaudited condensed combined statements of operations, the unaudited pro forma adjustments are expected to have a continuing impact on the combined results.
The unaudited pro forma condensed combined financial information is presented for informational purposes only and to aid you in your analysis of the financial aspects of the transactions. The unaudited pro forma condensed combined financial information described above has been derived from the historical financial statements of 180, KBL and the 180 Subsidiaries and the related notes. The unaudited pro forma condensed combined financial information is based on 180’s accounting policies. Further review may identify additional differences between the accounting policies of 180, KBL and the 180 Subsidiaries. The unaudited pro forma adjustments and the pro forma condensed combined financial information do not reflect the impact of synergies or post-transaction management actions and are not necessarily indicative of the financial position or results of operations that may have actually occurred had the transactions taken place on the dates noted, or of 180’s future financial position or operating results.
Pursuant to KBL’s Charter, public stockholders were offered the opportunity to redeem, upon the Closing, shares of KBL Common Stock then held by them for cash equal to their pro rata share of the aggregate amount on deposit in the Trust Account. On November 5, 2020, stockholders holding 816,461 public shares exercised their right to redeem such public shares into a pro rata portion of the Trust Account, also prior to September 30, 2020 106,186 shares were redeemed. As a result, an aggregate of approximately $10,167,188 was removed from the Trust Account to pay such holders. November 5, 2020 was the last day for stockholders to redeem any shares of the Company.
1 | P a g e
180 LIFE SCIENCES CORP.
BUSINESS COMBINATION
Unaudited Pro Forma Condensed Combined Balance Sheet (as restated)
June 30, 2020
| 180 | KBL (as restated) | KBL Pro Forma Adjustments | KBL As Adjusted | Pro
Forma Adjustments | Intercompany Eliminations | Pro Forma Combined | ||||||||||||||||||||||||
| Note A | Note B | Note C | Note D | Note E | ||||||||||||||||||||||||||
| Assets | ||||||||||||||||||||||||||||||
| Current Assets: | ||||||||||||||||||||||||||||||
| Cash | $ | 70,127 | $ | 257,601 | $ | 8,295,757 | (a),(b) | $ | 8,553,358 | $ | - | $ | - | $ | 8,623,485 | |||||||||||||||
| Restricted cash | - | 787,865 | 2,212,135 | (b) | 3,000,000 | - | - | 3,000,000 | ||||||||||||||||||||||
| Due from related parties | 321,904 | - | - | - | - | - | 321,904 | |||||||||||||||||||||||
| Prepaid income taxes | - | 21,806 | - | 21,806 | - | - | 21,806 | |||||||||||||||||||||||
| Prepaid expenses and other current assets | 160,511 | 118,645 | - | 118,645 | - | - | 279,156 | |||||||||||||||||||||||
| Total Current Assets | 552,542 | 1,185,917 | 10,507,892 | 11,693,809 | - | - | 12,246,351 | |||||||||||||||||||||||
| Cash and marketable securities held in Trust Account | - | 11,276,350 | (11,276,350 | ) | (a) | - | - | - | - | |||||||||||||||||||||
| Other assets | - | 163,797 | - | 163,797 | - | - | 163,797 | |||||||||||||||||||||||
| Property and equipment, net | 44,077 | - | - | - | - | - | 44,077 | |||||||||||||||||||||||
| Intangible assets, net | 1,973,859 | - | - | - | - | - | 1,973,859 | |||||||||||||||||||||||
| In-process research and development | 12,462,429 | - | - | - | - | - | 12,462,429 | |||||||||||||||||||||||
| Goodwill | 35,339,135 | - | - | - | - | - | 35,339,135 | |||||||||||||||||||||||
| Total Assets | $ | 50,372,042 | $ | 12,626,064 | $ | (768,458 | ) | $ | 11,857,606 | $ | - | $ | - | $ | 62,229,648 | |||||||||||||||
| Liabilities and Stockholders’ Equity | ||||||||||||||||||||||||||||||
| Current Liabilities: | ||||||||||||||||||||||||||||||
| Accounts payable and accrued expenses | $ | 7,063,216 | $ | 995,052 | $ | 3,407,572 | (a),(b) | $ | 4,402,624 | $ | 459,444 | (b),(c) | $ | - | $ | 11,925,284 | ||||||||||||||
| Accounts payable and accrued expenses - related party | 386,244 | - | - | - | (3,064 | ) | (c) | - | 383,180 | |||||||||||||||||||||
| Accrued issuable equity | - | 96,011 | 103,402 | (b) | 199,413 | - | - | 199,413 | ||||||||||||||||||||||
| Convertible promissory note - related party | - | 337,301 | - | 337,301 | - | - | 337,301 | |||||||||||||||||||||||
| Advances due - 180 | - | 1,379,815 | - | 1,379,815 | - | (1,379,815 | ) | - | ||||||||||||||||||||||
| Due to related parties, net | 25,187 | 795,003 | (795,003 | ) | (b) | - | - | - | 25,187 | |||||||||||||||||||||
| Loans payable | 145,054 | - | - | - | - | - | 145,054 | |||||||||||||||||||||||
| Loans payable - related parties | 440,756 | - | - | - | - | - | 440,756 | |||||||||||||||||||||||
| Convertible notes payable, net of discount | - | 324,264 | - | 324,264 | - | - | 324,264 | |||||||||||||||||||||||
| Derivative liability | - | 214,188 | - | 214,188 | - | - | 214,188 | |||||||||||||||||||||||
| Total Current Liabilities | 8,060,457 | 4,141,634 | 2,715,971 | 6,857,605 | 456,380 | (1,379,815 | ) | 13,994,627 | ||||||||||||||||||||||
| Loans payable - non current portion | 246,914 | - | - | - | - | - | 246,914 | |||||||||||||||||||||||
| Convertible notes payable - non current portion | 2,035,164 | - | - | - | (1,702,664 | ) | (c) | - | 332,500 | |||||||||||||||||||||
| Convertible notes payable - related parties - non current portion | 523,609 | - | - | - | (253,609 | ) | (c) | - | 270,000 | |||||||||||||||||||||
| Deferred tax liability | 3,624,036 | - | - | - | - | - | 3,624,036 | |||||||||||||||||||||||
| Total Liabilities | 14,490,180 | 4,141,634 | 2,715,971 | 6,857,605 | (1,499,893 | ) | (1,379,815 | ) | 18,468,077 | |||||||||||||||||||||
| Commitments and Contingencies | ||||||||||||||||||||||||||||||
| Preferred stock, subject to redemption | - | - | 2,603,265 | (b) | 2,603,265 | - | - | 2,603,265 | ||||||||||||||||||||||
| Common stock, subject to redemption | - | 3,484,422 | (3,484,422 | ) | (a) | - | - | - | - | |||||||||||||||||||||
| Stockholders’ Equity: | ||||||||||||||||||||||||||||||
| Preferred stock | - | - | - | - | - | - | - | |||||||||||||||||||||||
| Common stock | 8 | 514 | 221 | (a),(b) | 735 | 1,789 | (a),(c) | - | 2,532 | |||||||||||||||||||||
| Additional-paid in capital | 76,293,471 | 9,583,392 | 1,913,246 | (a),(b) | 11,496,638 | (7,142,587 | ) | (a),(b),(c) | - | 80,647,522 | ||||||||||||||||||||
| Accumulated other comprehensive income | (824,158 | ) | - | - | - | - | - | (824,158 | ) | |||||||||||||||||||||
| Retained earnings/accumulated deficit | (39,587,459 | ) | (4,583,898 | ) | (4,516,739 | ) | (9,100,637 | ) | 8,640,691 | (b) | 1,379,815 | (38,667,590 | ) | |||||||||||||||||
| Total Stockholders’ Equity | 35,881,862 | 5,000,008 | (2,603,272 | ) | 2,396,736 | 1,499,893 | 1,379,815 | 41,158,306 | ||||||||||||||||||||||
| Total Liabilities and Stockholders’ Equity | $ | 50,372,042 | $ | 12,626,064 | $ | (768,458 | ) | $ | 11,857,606 | $ | - | $ | - | $ | 62,229,648 | |||||||||||||||
See notes to the unaudited pro forma condensed combined financial information
2 | P a g e
180 LIFE SCIENCES CORP.
BUSINESS COMBINATION
Unaudited Pro Forma Condensed Combined Statement of Operations (as restated)
For the Six Months Ended June 30, 2020
| 180 | KBL (as restated) | Pro Forma Adjustments | Pro
Forma Combined | ||||||||||||||
| Note A | Note B | Note C | |||||||||||||||
| Operating Expenses: | |||||||||||||||||
| Research and development | $ | 704,800 | $ | - | $ | - | $ | 704,800 | |||||||||
| General and administrative-related parties | 96,402 | - | - | 96,402 | |||||||||||||
| General and administrative | 1,699,859 | 3,760,631 | (3,838,145 | ) | (a) | 1,622,345 | |||||||||||
| Total Operating Expenses | 2,501,061 | 3,760,631 | (3,838,145 | ) | 2,423,547 | ||||||||||||
| Loss From Operations | (2,501,061 | ) | (3,760,631 | ) | 3,838,145 | (2,423,547 | ) | ||||||||||
| Other Income (Expense): | |||||||||||||||||
| Other income - related parties | 240,000 | - | - | 240,000 | |||||||||||||
| Other income | 12,605 | - | - | 12,605 | |||||||||||||
| Interest income | - | 38,438 | (38,438 | ) | (b) | - | |||||||||||
| Interest expense | (325,414 | ) | (270,257 | ) | 245,098 | (b) | (350,573 | ) | |||||||||
| Interest expense - related party | (41,670 | ) | - | 18,365 | (b) | (23,305 | ) | ||||||||||
| Loss on issuance of convertible promissory note | - | (1,657,522 | ) | - | (1,657,522 | ) | |||||||||||
| Gain on extinguishment, net | 491,624 | - | - | 491,624 | |||||||||||||
| Total Other Income (Expense) | 377,145 | (1,889,341 | ) | 225,025 | (1,287,171 | ) | |||||||||||
| (Loss) Income Before Provision for Income Taxes | (2,123,916 | ) | (5,649,972 | ) | 4,063,170 | (3,710,718 | ) | ||||||||||
| Income tax benefit (provision) | 10,038 | (3,827 | ) | 3,827 | (c) | 10,038 | |||||||||||
| Net Loss | $ | (2,113,878 | ) | $ | (5,653,799 | ) | $ | 4,066,997 | $ | (3,700,680 | ) | ||||||
| Loss per share: | |||||||||||||||||
| Basic | $ | (25.07 | ) | $ | (1.27 | ) | $ | (0.16 | ) | ||||||||
| Diluted | $ | (25.07 | ) | $ | (1.27 | ) | $ | (0.16 | ) | ||||||||
| Number of common shares outstanding | |||||||||||||||||
| Basic | 84,326 | 4,468,714 | 19,058,675 | (d) | 23,527,389 | ||||||||||||
| Diluted | 84,326 | 4,468,714 | 19,058,675 | (d) | 23,527,389 | ||||||||||||
See notes to the unaudited pro forma condensed combined financial information
3 | P a g e
180 LIFE SCIENCES CORP.
BUSINESS COMBINATION
Unaudited Pro Forma Condensed Combined Statement of Operations
For the Year Ended December 31, 2019
| 180 | KBL | Pro
Forma Adjustments | Pro
Forma Combined | ||||||||||||||
| Note A | Note B | Note C | |||||||||||||||
| Operating Expenses: | |||||||||||||||||
| Research and development | $ | 2,794,716 | $ | - | $ | - | $ | 2,794,716 | |||||||||
| Rental income -related parties | (170,872 | ) | - | - | (170,872 | ) | |||||||||||
| General and administrative | 7,976,030 | 1,208,943 | (672,304 | ) | (a) | 8,512,669 | |||||||||||
| Modification of stock award - related parties | 12,959,360 | - | - | 12,959,360 | |||||||||||||
| General and administrative -related parties | 473,425 | - | - | 473,425 | |||||||||||||
| Total Operating Expenses | 24,032,659 | 1,208,943 | (672,304 | ) | 24,569,298 | ||||||||||||
| Loss From Operations | (24,032,659 | ) | (1,208,943 | ) | 672,304 | (24,569,298 | ) | ||||||||||
| Other Income (Expense): | |||||||||||||||||
| Gain on sale of property and equipment | 1,714 | - | - | 1,714 | |||||||||||||
| Other income, net | 407,651 | - | - | 407,651 | |||||||||||||
| Other income - related parties | 552,329 | - | - | 552,329 | |||||||||||||
| Interest income | 4,039 | 1,374,898 | (1,374,898 | ) | (b) | 4,039 | |||||||||||
| Interest income -related parties | 2,170 | - | - | 2,170 | |||||||||||||
| Interest expense | (160,185 | ) | - | 123,112 | (b) | (37,073 | ) | ||||||||||
| Interest expense -related parties | (30,563 | ) | - | 9,604 | (b) | (20,959 | ) | ||||||||||
| Loss on extinguishment on convertible notes payable | (703,188 | ) | - | - | (703,188 | ) | |||||||||||
| Change in fair value of accrued issuable equity | (327,879 | ) | - | - | (327,879 | ) | |||||||||||
| Change in fair value of accrued issuable equity-related parties | (3,893,086 | ) | - | - | (3,893,086 | ) | |||||||||||
| Total Other Income (Expense) | (4,146,998 | ) | 1,374,898 | (1,242,182 | ) | (4,014,282 | ) | ||||||||||
| Income (Loss) Before Provision for Income Taxes | (28,179,657 | ) | 165,955 | (569,878 | ) | (28,583,580 | ) | ||||||||||
| Income tax benefit (provision) | 20,076 | (257,255 | ) | 257,255 | (c) | 20,076 | |||||||||||
| Net Loss | $ | (28,159,581 | ) | $ | (91,300 | ) | $ | (312,623 | ) | $ | (28,563,504 | ) | |||||
| Loss per share: | |||||||||||||||||
| Basic (restated) | $ | (281.60 | ) | $ | (0.02 | ) | $ | (1.24 | ) | ||||||||
| Diluted (restated) | $ | (281.60 | ) | $ | (0.02 | ) | $ | (1.24 | ) | ||||||||
| Number of common shares outstanding | |||||||||||||||||
| Basic (restated) | 100,000 | 4,223,791 | 18,674,074 | (d) | 22,997,865 | ||||||||||||
| Diluted (restated) | 100,000 | 4,223,791 | 18,674,074 | (d) | 22,997,865 | ||||||||||||
See notes to the unaudited pro forma condensed combined financial information
4 | P a g e
Basis of Presentation
The unaudited pro forma condensed combined financial information set forth herein is based upon the unaudited pro forma condensed combined financial statements of 180 and the financial statements of KBL. The unaudited pro forma condensed combined financial information is presented as if the business combination had been completed on January 1, 2019 with respect to the unaudited pro forma condensed combined statements of operations for the six months ended June 30, 2020 and for the year ended December 31, 2019 and on June 30, 2020 in respect of the unaudited pro forma condensed combined balance sheet.
The unaudited pro forma condensed combined financial information is presented for informational purposes only and is not necessarily indicative of the combined financial position or results of operations had the business combination occurred as of the date indicated, nor is it meant to be indicative of any anticipated combined financial position or future results of operations that the combined company will experience after the completion of the business combination.
We have accounted for the business combination in these unaudited pro forma condensed combined financial statements as a reverse recapitalization, in accordance with Financial Accounting Standards Board (“FASB”) Accounting Standards Codification Topic 805 “Business Combinations” (“ASC 805”). In accordance with ASC 805, this is a capital transaction of 180 (the legal acquiree) and is the equivalent to the issuance of shares by 180 for the net monetary assets of KBL, accompanied by a recapitalization.
Pro forma adjustments reflected in the unaudited pro forma condensed combined balance sheet are based on items that are factually supportable and directly attributable to the business combination. Pro forma adjustments reflected in the pro forma condensed combined statements of income are based on items that are factually supportable, directly attributable to the business combination and are expected to have a continuing impact on the combined results. The unaudited pro forma condensed combined financial information does not reflect the cost of any integration activities or benefits from the business combination, including potential synergies that may be generated in future periods.
5 | P a g e
Pro Forma Adjustments
Potential Legal Matters
The Company may initiate legal action against former executives of KBL for non-disclosure in its June 30, 2020 and September 30, 2020 financial statements of the matters recently disclosed in the Amended Quarterly Reports on Form 10-Q for such periods (the “Amended Reports”). If such legal action is initiated, the Company would seek damages to cover, at a minimum, the unrecorded and contingent liability obligations and legal fees discussed in the Amended Reports. There can be no assurance that, if such legal action is initiated, that the Company will be successful in its legal actions. The unaudited pro forma combined financial statements do not reflect any potential recovery for such items, given that the realization of cash flows associated with the gain contingency are not relatively certain.
The following pro forma adjustments give effect to the business combination.
Unaudited Pro Forma Condensed Combined Balance Sheet – As of June 30, 2020
| Note A | Derived from the unaudited pro forma condensed combined balance sheet of 180 as of June 30, 2020 included elsewhere in this filing. | |
| Note B | Derived from the unaudited restated condensed balance sheet of KBL as of June 30, 2020. |
Pro Forma Adjustments:
| Note C | (a) | To give effect to the transfer of 334,880 shares of common stock, subject to redemption with a carrying value of $3,484,422, to permanent equity (adds $33 of par value).
To give effect to the redemption of 922,647 shares (subtracts $92 of par value) of common stock with an aggregate cash payment of $10,167,188.
To give effect to an additional issuance of 648,873 IPO shares (adds par value of $65) of common stock at $10.00 per share for aggregate gross proceeds of $6,488,730 pursuant to a Guarantee and Commitment Agreement whereby Tyche will purchase enough shares of KBL common stock to ensure that KBL has $5,000,001 in net tangible assets at closing of the Business Combination. It should be noted that, as of the filing date, Tyche has not fulfilled its obligations pursuant to the Guarantee and Commitment Agreement.
The remaining $11,276,350 of cash from the Trust Account has been reclassified to unrestricted cash. And to also give effect to the issuance of 1,200,250 shares (increase in par value of $120) pursuant to certain KBL shareholder rights.
To give effect to the issuance of 250,000 shares of KBL common stock to certain vendors (adds par value of $25) for total compensation of $1,312,500 at the closing of the Business Combination. Furthermore, to give effect to the issuance of 500,000 shares of KBL common stock (previously recorded as stock-based compensation) pursuant to a severance agreements (adds par value of $50).
To reflect a contractual cash payment of $90,000 to a certain vendor upon transfer of the remaining funds from the trust account into unrestricted cash.
To reflect a $1,454,239 accrual for legal fees due, when and if, the Company closes the business combination.
To reflect a $1,750,000 accrual for investment banking success fees earned at the closing of the business combination. | |
| (b) | On June 26, 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) dated June 12, 2020, whereby upon the second closing pursuant to the SPA, upon the completion of the Business Combination and the registration statement becoming effective, as well as certain other conditions being satisfied, the Company shall have the right to have a certain investor purchase all of the authorized Series A Convertible Preferred Stock (1,000,000 shares) of the Company for an aggregate purchase price of $3,000,000. In connection with the issuance of the Series A Convertible Preferred Stock, the Company incurred issuance costs of $396,735 in the form of cash ($293,333) and warrants ($103,402) recorded as a discount to the face value of the preferred stock. |
6 | P a g e
The Preferred Stock shall be convertible into common stock at a conversion price of $5.28 per share at the election of the holder at any time following issuance, subject to adjustment.
At any time following the three-month anniversary of the Business Combination, the holder of the Preferred Stock has the right to force the Company to redeem all or any portion of the Preferred Stock then owned by the holder in cash hence the preferred stock classified as temporary equity. The Series A Convertible Preferred Stock redemption features require bifurcation, however the value was indeterminable as of the date of the pro forma balance sheet. As a result, the Company did not recognize a separated component at its fair value related to the redemption features in these pro forma financial statements.
Subsequent to the closing of the Business Combination and prior to the filing date of this report, all of the holders of preferred stock elected to convert their entire preferred stock holdings into shares of KBL common stock. These conversions were not directly related to the Business Combination and have not been reflected in these pro forma financial statements.
To give effect to the conversion of $795,003 of KBL due to related parties and $0 of accrued interest into 198,751 shares of KBL common stock (adds par value of $20).
Furthermore, to give effect to the release of $787,865 of restricted cash into unrestricted cash at the time of the business combination. |
| Note D | (a) | To give effect to the reverse recapitalization whereby KBL will issue 17,500,000 shares (adds par value of $1,750) of KBL Common Stock to the shareholders of 180 and the elimination of 85,050 shares (decrease in par value of $8) of 180 common stock. | |
| (b) | To give effect to an additional $459,946 of 180 merger expenses to be incurred subsequent to June 30, 2020 with an offset to accounts payable. Also, to eliminate KBL’s $9,100,637 accumulated deficit. | ||
| (c) | To give effect to the conversion of $1,702,664 of convertible notes and $502 of accrued interest into 419,625 shares of KBL common stock (adds par value of $42). To give effect to the conversion of $253,609 of convertible notes — related parties and $3,064 of accrued interest — related parties into 63,269 shares of KBL common stock (adds par value of $6). Subsequent to June 30, 2020 certain holders of preferred stock elected to convert. These conversions were not directly related to the Business Combination and have not been reflected in these pro forma financial statements. |
| Note E | To reverse $1,379,815 of bad debt allowance on 180’s books and then to eliminate the intercompany loans between 180 and KBL. | |
| Note F | The below table illustrates the allocation of ownership interests in the combined entity. |
| June 30, 2020 | Number of Shares | |||
| KBL outstanding shares | 5,139,222 | |||
| Shares redeemed | (922,647 | ) | ||
| Shares reclassified from temporary equity to permanent equity | 334,880 | |||
| Shares issuable to 180 shareholders (1) | 17,500,000 | |||
| Conversion of rights into shares of KBL | 1,200,250 | |||
| Tyche backstop shares, after purchase | 648,873 | |||
| Automatic conversion of debt | 681,645 | |||
| Shares issued for success fees | 250,000 | |||
| Shares issued pursuant to severance agreement | 500,000 | |||
| 25,332,223 | ||||
| (1) | Certain Canadian shareholders have the ability to elect to receive Exchangeable Shares held in the form of preferred stock in 180. For pro forma purposes the Company has assumed all Exchangeable Shares have been converted into KBL Common Stock. |
7 | P a g e
Unaudited Pro Forma Condensed Combined Statement of Operations For The Six Months Ended June 30, 2020
| Note A | Derived from the unaudited condensed consolidated statement of operations of 180 for the six months ended June 30, 2020 included elsewhere in this filing. | |
| Note B | Derived from the unaudited restated condensed statement of operations of KBL for the six months ended June 30, 2020. |
Pro Forma Adjustments:
| Note C | a) | To give effect to a new employment agreement whereby a new executive will receive aggregate cash compensation of $180,000 (which represents the six month effect of base year cash compensation of $360,000). Furthermore, to eliminate $893,145 of non-recurring merger related expenses and $3,125,000 of severance expenses related to the KBL CEO. | |
| b) | To eliminate interest income derived from KBL’s investment account as the cash within the investment account would have likely been reclassified to a non-interest bearing account upon the Closing. To eliminate aggregate interest expense of $245,098 related to notes payable that will be converted upon close of the business combination. To eliminate aggregate interest expense – related party of $18,365 related to notes payable that will be converted upon close of the business combination. | ||
| c) | To eliminate the KBL income tax provision as the combined entity is expected to incur a loss during the period. |
| d) | The below table illustrates the adjustment to the weighted average shares outstanding used in the earnings per share calculations for the 17,500,000 shares of KBL Common Stock issued as consideration to the 180 stockholders, less the 1,050,000 holdback shares (6% of the 17,500,000 shares issuable to the 180 stockholders, which will be held in escrow for 12 months in order to satisfy any potential indemnification claims of KBL, plus 681,645 shares issuable upon the automatic conversion of certain convertible debt, plus the 334,880 remaining redeemable shares of KBL Common Stock reclassified from temporary equity to permanent equity, the 1,200,250 shares of KBL Common Stock issued as a result of conversion of rights, the issuance of 250,000 shares of common stock related to investment banking success fees plus the issuance of 500,000 shares related to an severance agreement, plus 648,873 Tyche backstop shares, less 922,647 shares redeemed, less the 84,326 shares outstanding of 180 common stock. The diluted loss per share data is calculated based on net loss divided by the weighted average shares outstanding. |
| June 30, 2020 | Weighted Average Number of Shares | |||
| Share consideration for transaction | 17,500,000 | |||
| Holdback shares | (1,050,000 | ) | ||
| Shares redeemed | (922,647 | ) | ||
| Automatic conversion of debt | 681,645 | |||
| Tyche backstop shares, after purchase | 648,873 | |||
| Reclassification from temporary equity to permanent equity | 334,880 | |||
| Conversion of rights into shares of KBL | 1,200,250 | |||
| Shares issued for success fees | 250,000 | |||
| Shares issued pursuant to severance agreement | 500,000 | |||
| Elimination of 180’s weighted average equity | (84,326 | ) | ||
| Total adjustment | 19,058,675 | |||
8 | P a g e
Unaudited Pro Forma Condensed Combined Statement of Operations For The Year Ended December 31, 2019
| Note A | Derived from the unaudited pro forma condensed combined statement of operations of 180 for the year ended December 31, 2019 included elsewhere in this filing. | |
| Note B | Derived from the audited statement of operations of KBL for the year ended December 31, 2019. |
Pro Forma Adjustments:
| Note C | a) | To give effect to a new employment agreement whereby a new executive will receive aggregate cash compensation of $250,000. Furthermore, to eliminate $922,304 of non-recurring merger related expenses. | |
| b) | To eliminate interest income derived from KBL’s investment account as the cash within the investment account would have likely been reclassified to a non-interest bearing account upon the Closing. To eliminate aggregate interest expense of $132,716 related to notes payable that will be converted upon close of the business combination. | ||
| c) | To eliminate the KBL income tax provision as the combined entity is expected to incur a loss during the period. | ||
| d) | The below table illustrates the adjustment to the weighted average shares outstanding used in the earnings per share calculations for the 17,500,000 shares of KBL Common Stock issued as consideration to the 180 stockholders, less the 1,050,000 holdback shares (6% of the 17,500,000 shares issuable to the 180 stockholders, which will be held in escrow for 12 months in order to satisfy any potential indemnification claims of KBL, plus 681,645 shares issuable upon the automatic conversion of certain convertible debt, plus the 33,618 remaining redeemable shares of KBL Common Stock reclassified from temporary equity to permanent equity, the 1,200,250 shares of KBL Common Stock issued as a result of conversion of rights, the issuance of 250,000 shares of common stock related to investment banking success fees plus the issuance of 500,000 shares related to an severance agreement, plus 648,873 Tyche backstop shares, less 990,312 shares redeemed, less the 84,326 shares outstanding of 180 common stock. The diluted loss per share data is calculated based on net loss divided by the weighted average shares outstanding. |
| December 31, 2019 | (as
restated) Weighted Average Number of Shares | |||
| Share consideration for transaction | 17,500,000 | |||
| Holdback shares | (1,050,000 | ) | ||
| Shares redeemed | (990,312 | ) | ||
| Automatic conversion of debt | 681,645 | |||
| Tyche backstop shares, after purchase | 648,873 | |||
| Reclassification from temporary equity to permanent equity | 33,618 | |||
| Shares issued pursuant to severance agreement | 500,000 | |||
| Shares issued for success fees | 250,000 | |||
| Conversion of rights into shares of KBL | 1,200,250 | |||
| Elimination of CannBioRx’s historical equity | (100,000 | ) | ||
| Total adjustment | 18,674,074 | |||
9 | P a g e
180 LIFE SCIENCES CORP.
REORGANIZATION
Unaudited Pro Forma Condensed Combined Statement of Operations
For the Year Ended December 31, 2019
| 180 | CBR Pharma | 180 LP | CannBioRx | Pro Forma Adjustments | Intercompany Eliminations | Pro Forma Combined | ||||||||||||||||||||||||
| Note A | Note B | Note C | Note D | Note E | Note F | |||||||||||||||||||||||||
| Operating Expenses: | ||||||||||||||||||||||||||||||
| Research and development | $ | 1,887,402 | $ | 623,578 | $ | 283,736 | $ | - | $ | - | $ | - | $ | 2,794,716 | ||||||||||||||||
| Rental income - related parties | (25,946 | ) | (186,688 | ) | - | - | - | 41,762 | (170,872 | ) | ||||||||||||||||||||
| General and administrative | 5,701,705 | 2,284,027 | 882,848 | 1,730,334 | (1,267,662 | ) | (a),(c) | (1,355,222 | ) | 7,976,030 | ||||||||||||||||||||
| Modification of stock award-related parties | 12,959,360 | - | - | - | - | - | 12,959,360 | |||||||||||||||||||||||
| General and administrative - related parties | 340,765 | 132,660 | - | - | - | - | 473,425 | |||||||||||||||||||||||
| Total Operating Expenses | 20,863,286 | 2,853,577 | 1,166,584 | 1,730,334 | (1,267,662 | ) | (1,313,460 | ) | 24,032,659 | |||||||||||||||||||||
| Loss From Operations | (20,863,286 | ) | (2,853,577 | ) | (1,166,584 | ) | (1,730,334 | ) | 1,267,662 | 1,313,460 | (24,032,659 | ) | ||||||||||||||||||
| Other Income (Expense): | ||||||||||||||||||||||||||||||
| Gain on sale of property and equipment | 1,714 | - | - | - | - | - | 1,714 | |||||||||||||||||||||||
| Other income, net | - | - | 407,651 | - | - | - | 407,651 | |||||||||||||||||||||||
| Other income - related parties | 552,329 | - | - | - | - | - | 552,329 | |||||||||||||||||||||||
| Interest income | 3,727 | 2,193 | - | - | - | (1,881 | ) | 4,039 | ||||||||||||||||||||||
| Interest income - related parties | - | 2,170 | - | - | - | - | 2,170 | |||||||||||||||||||||||
| Interest expense - related parties | (23,074 | ) | - | (7,489 | ) | - | - | - | (30,563 | ) | ||||||||||||||||||||
| Interest expense | (162,066 | ) | - | - | - | - | 1,881 | (160,185 | ) | |||||||||||||||||||||
| Loss on extinguishment on convertible notes payable | (703,188 | ) | - | - | - | - | - | (703,188 | ) | |||||||||||||||||||||
| Change in fair value of accrued issuable equity | (327,879 | ) | - | - | - | - | - | (327,879 | ) | |||||||||||||||||||||
| Change in fair value of accrued issuable equity - related parties | (3,881,819 | ) | (11,267 | ) | - | - | - | - | (3,893,086 | ) | ||||||||||||||||||||
| Total Other Income (Expense) | (4,540,256 | ) | (6,904 | ) | 400,162 | - | - | - | (4,146,998 | ) | ||||||||||||||||||||
| (Loss) Income Before Provision for Income Taxes | (25,403,542 | ) | (2,860,481 | ) | (766,422 | ) | (1,730,334 | ) | 1,267,662 | 1,313,460 | (28,179,657 | ) | ||||||||||||||||||
| Provision for income taxes | 9,496 | - | - | - | 10,580 | (c) | - | 20,076 | ||||||||||||||||||||||
| Net Loss | $ | (25,394,046 | ) | $ | (2,860,481 | ) | $ | (766,422 | ) | $ | (1,730,334 | ) | $ | 1,278,242 | $ | 1,313,460 | $ | (28,159,581 | ) | |||||||||||
| Earnings per share: | ||||||||||||||||||||||||||||||
| Basic | $ | (405.52 | ) | $ | (281.60 | ) | ||||||||||||||||||||||||
| Diluted | $ | (405.52 | ) | $ | (281.60 | ) | ||||||||||||||||||||||||
| Number of common shares outstanding | ||||||||||||||||||||||||||||||
| Basic | 62,621 | 37,379 | (b) | 100,000 | ||||||||||||||||||||||||||
| Diluted | 62,621 | 37,379 | (b) | 100,000 | ||||||||||||||||||||||||||
See notes to the unaudited pro forma condensed combined financial information
10 | P a g e
Basis of Presentation
The unaudited pro forma condensed combined financial information set forth herein is based upon the financial statements of 180 (inclusive of Katexco, the accounting acquirer, plus the historical pre-Reorganization financial statements of CannBioRx, CBR Pharma and 180 LP (collectively the accounting acquirees). The unaudited pro forma condensed combined financial information is presented as if the Reorganization had been completed on January 1, 2019 with respect to the unaudited pro forma condensed combined statement of operations for the year ended December 31, 2019. No 2020 pro forma condensed combined Reorganization financial statements are presented because the June 30, 2020 financial statements of 180, included elsewhere in this filing, represent the June 30, 2020 consolidated balance sheet of 180 and the 180 Subsidiaries following the July 16, 2019 Reorganization.
The unaudited pro forma condensed combined financial information is presented for informational purposes only and is not necessarily indicative of the combined results of operations had the Reorganization occurred as of the date indicated, nor is it meant to be indicative of any anticipated combined future results of operations that the combined company will experience after the completion of the Reorganization.
We have accounted for the Reorganization using the acquisition method of accounting, in accordance with ASC 805. In accordance with ASC 805, we used our best estimates and assumptions to assign fair values to the tangible and intangible assets acquired and liabilities assumed at the acquisition date. Goodwill as of the acquisition date was measured as the excess of the purchase consideration over the fair value of the net tangible and identifiable intangible assets acquired.
Pro forma adjustments reflected in the pro forma condensed combined statements of income are based on items that are factually supportable, are directly attributable to the Reorganization, and are expected to have a continuing impact on the combined results. The unaudited pro forma condensed combined financial information does not reflect the cost of any integration activities or benefits from the Reorganization, including potential synergies that may be generated in future periods.
Pro Forma Adjustments
The following pro forma adjustments give effect to the Reorganization.
Unaudited
Pro Forma Condensed Combined Statement of Operations For The Year Ended December 31, 2019
| Note A | Derived from the unaudited consolidated statement of operations of 180 for the year ended December 31, 2019 included elsewhere in this filing. | |
| Note B | Derived from the unaudited statement of operations of CBR Pharma for the six months ended June 30, 2019 included elsewhere in this filing, as adjusted for the results from July 1, 2019 to July 16, 2019. |
| Six
Months Ended June 30, 2019 | Period From July 1, 2019 through July 16, 2019 | Period From January 1, 2019 through July 16, 2019 | ||||||||||
| CBR Pharma | CBR Pharma | CBR Pharma | ||||||||||
| Operating expenses (income): | ||||||||||||
| Research and development | $ | 578,216 | $ | 45,362 | $ | 623,578 | ||||||
| General and administrative | 2,100,806 | 183,221 | 2,284,027 | |||||||||
| Rental income - related parties | (182,616 | ) | (4,072 | ) | (186,688 | ) | ||||||
| General and administrative - related parties | 121,734 | 10,926 | 132,660 | |||||||||
| Loss from operations | (2,618,140 | ) | (235,437 | ) | (2,853,577 | ) | ||||||
| Interest income | 2,186 | 6 | 2,193 | |||||||||
| Interest income - related parties | 2,170 | - | 2,170 | |||||||||
| Change in fair value of accrued issuable equity-related party | (11,249 | ) | (18 | ) | (11,267 | ) | ||||||
| Net loss | $ | (2,625,033 | ) | $ | (235,449 | ) | $ | (2,860,481 | ) | |||
11 | P a g e
| Note C | Derived from the unaudited statement of operations of 180 LP for the six months ended June 30, 2019 included elsewhere in this filing, as adjusted for the results from July 1, 2019 to July 16, 2019. |
| Six
Months Ended June 30, 2019 | Period
From July 1, 2019 through July 16, 2019 | Period
From July 16, 2019 | ||||||||||
| 180 LP | 180 LP | 180 LP | ||||||||||
| Operating expenses: | ||||||||||||
| Research and development | $ | 246,260 | $ | 37,476 | $ | 283,736 | ||||||
| General and administrative | 824,265 | 58,583 | 882,848 | |||||||||
| Loss from operations | (1,070,525 | ) | (96,059 | ) | (1,166,584 | ) | ||||||
| Other income - related party | 340,968 | 66,683 | 407,651 | |||||||||
| Interest expense - related parties | (6,882 | ) | (607 | ) | (7,489 | ) | ||||||
| Net loss | $ | (736,439 | ) | $ | (29,983 | ) | $ | (766,422 | ) | |||
| Note D | Derived from the unaudited statement of operations of CannBioRx for the six months ended June 30, 2019 included elsewhere in this filing, as adjusted for the results from July 1, 2019 to July 16, 2019, as shown in the table below. |
| Six
Months Ended June 30, 2019 | Period
From July 1, 2019 through July 16, 2019 | Period
From January 1, 2019 through July 16, 2019 | ||||||||||
| CBR-LS | CBR-LS | CBR-LS | ||||||||||
| Operating expenses: | ||||||||||||
| General and administrative | $ | 1,050,000 | $ | 680,334 | $ | 1,730,334 | ||||||
| Loss from operations | (1,050,000 | ) | (680,334 | ) | (1,730,334 | ) | ||||||
| Net loss | $ | (1,050,000 | ) | $ | (680,334 | ) | $ | (1,730,334 | ) | |||
Pro Forma Adjustments:
| Note E | a) | To eliminate $1,327,998 merger expenses. | |
| b) | To adjust the weighted average shares for the full year effect of the shares issued in the Reorganization, as if the Reorganization occurred on January 1, 2019. The weighted average shares outstanding used in the pro forma combined loss per share calculations reflect 62,621 shares of 180 common stock issued as consideration to the former stockholders of the accounting acquirees and 37,379 shares of 180 common stock issued to the former Katexco stockholders. The diluted loss per share data is calculated based on net loss divided by the weighted average dilutive shares outstanding. | ||
| c) | To give effect to incremental amortization expense of $60,336 related to the technology licenses and a corresponding income tax benefit. |
| Note F | To eliminate intercompany activity between 180, CBR Pharma, 180 LP and CannBioRx. |
12 | P a g e